🔗 Share this article

While the US proceeds with historic adjustments to its immunization guidelines, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccinations throughout the global health crisis and has focused upon possible fatalities following Covid vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Schedule

Agency leaders planned to unveil radical changes to the childhood immunization program in December, aligning the US with the Danish national calendar, sources say – a significant shift that would place the US out of step with many the global community with insufficient data for improved outcomes. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to run the office this year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

The new acting director has frequently advocated for halting certain pediatric immunization guidelines in the US to become more similar to Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccines – typically the purview of Dr. Prasad, chief of the FDA’s CBER – instead of medication approval.

Doubts Over Background

Høeg has no apparent experience in medication creation, regulation or management, which has been customary for previous heads of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, said Jonathan Howard. “She’s never run a scientific study. She is not versed in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “understand laws and regulations and the underlying principles of medication creation”, said Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who led the center have had.”

CDER has an immense portfolio at the FDA, the former commissioner emphasized.

“Everybody just focuses on the innovative therapies, but the generic program clears numerous generic drugs. There is also a biologic copycat branch, non-prescription drug unit and so forth, and every single one must be managed,” she said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant administrative element to the position, which oversees more than 5,000 staff members. “It is a huge management job, if you execute it properly,” she added.

Agency Reaction and Contentious Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among FDA leaders on immunizations, a press secretary said that the “concerns are based on inaccurate presumptions”.

“This background is consistent with the functions of her position,” the representative said, noting the time Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a controversial one-day medication authorization process that allegedly concerned her former heads. “By what process are these medications being selected for this fast-track system? Who takes the calls?” Dr. Howard said. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards less stringent rules of all drugs, except for vaccines.”

Established Track Record on Vaccines

With immunizations, Dr. Høeg has a clearer, if problematic, past, Howard said. She released a analysis using unverified public submissions to assess the rate of myocarditis following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Part of her “wish list” for the incoming government included changing rules for recently developed shots and ending “non-essential” immunizations, she said post-election on a audio program. At the FDA, Dr. Høeg has allegedly proposed preventing teenage boys from getting COVID-19 vaccinations.

“She’s an all-around ideologue who starts off with her beliefs and works backwards to fit the evidence in a very misleading, dishonest fashion,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|